| Literature DB >> 32632268 |
Arvind Dasari1, Van K Morris2, Carmen J Allegra3, Chloe Atreya4, Al B Benson5, Patrick Boland6, Ki Chung7, Mehmet S Copur8, Ryan B Corcoran9, Dustin A Deming10, Andrea Dwyer11, Maximilian Diehn12, Cathy Eng2, Thomas J George13, Marc J Gollub14, Rachel A Goodwin15, Stanley R Hamilton16, Jaclyn F Hechtman17, Howard Hochster18, Theodore S Hong19, Federico Innocenti20, Atif Iqbal21, Samuel A Jacobs22, Hagen F Kennecke23, James J Lee24, Christopher H Lieu25, Heinz-Josef Lenz26, O Wolf Lindwasser27, Clara Montagut28, Bruno Odisio29, Fang-Shu Ou30, Laura Porter31, Kanwal Raghav2, Deborah Schrag32, Aaron J Scott33, Qian Shi30, John H Strickler34, Alan Venook4, Rona Yaeger35, Greg Yothers36, Y Nancy You37, Jason A Zell38,39, Scott Kopetz2.
Abstract
An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal-Anal Task Forces of the United States National Cancer Institute convened a panel of multidisciplinary experts to summarize current data on the utility of ctDNA in the management of colorectal cancer and to provide guidance in promoting the efficient development and integration of this technology into clinical care. The panel focused on four key areas in which ctDNA has the potential to change clinical practice, including the detection of minimal residual disease, the management of patients with rectal cancer, monitoring responses to therapy, and tracking clonal dynamics in response to targeted therapies and other systemic treatments. The panel also provides general guidelines with relevance for ctDNA-related research efforts, irrespective of indication.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32632268 PMCID： PMC7790747 DOI： 10.1038/s41571-020-0392-0
Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 65.011